ABBV 基本面稳健、管理层优秀，但当前 272 的估值对新买入缺乏吸引力。
逐段跳播
名单上的下一家公司是AbbVie。这是我绝对买过的首批个股之一。它实际上是我长期持有的核心，一直放在我的钱包里。
the next The company on the list AbbVie. This is one of the first individual stocks that I absolutely bought it. It is actually the center Longer single Keep it in my wallet
名单上的公司AbbVie。这是我绝对买过的首批个股之一。它实际上是我长期持有的核心，一直放在我的钱包里。嗯，它只是一个名字。很棒，他做了不少事情。我已经转变了，因为它依赖于首个领先药物Humira，如今随着Rinvoq和Skyrizi之类的东西变得更加多元化。
因此，管理层非常出色。向他们致敬。这里的评分是72。我同意，然而在272的价格下，估值并不像它应有的那样令人信服。所以从那个角度看，这降低了评分，但总体而言，它很强劲。
The company on the list AbbVie. This is one of the first individual shares that I absolutely bought it. It is actually the center Longer single Keep it in my wallet . Um, it's just a name.
Wonderful, he did a number Things. I have moved Because it depends on The first leading drug Humira to the works More diverse now with " Rinvoq and Skyrizi and things Something like that.
Therefore, Excellent management. Greetings to them. The score is 72 here. I agree However, at a price of 272, The evaluation is not Convincing as it should be. So This reduces the score From that perspective, but Overall, it's strong.
这个频道对 $ABBV 的历次判断
Mark Roussin, CPA 在这只股票上共 2 条判断，这里只列相邻的几条。